Achieve Life Sciences, Inc.
ACHV- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000949858
No open-market purchases or sales by Achieve Life Sciences, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q3 2026, worth $787.4M in total; no superinvestor holds it.
Other share classesQUIT
Key figures
- Market capClose on Nov 20, 2026
- $611.8M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +22 vs. previous quarter
- 131
- 13F valueReported value at the end of Q3 2026
- $787.4M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$54.6M
- No comparable prior period
- Free cash flow, FY2025
- -$49.5M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 18.1M
- Shares sold short
- Change
- +326.5K
- +1.8% vs. previous
- Days to cover
- 13.58
- At average daily volume
Superinvestors holding ACHV, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding ACHV at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Achieve Life Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 (view filing)4:30 PM ET | Aug 19 | 2 days | Stewart Richard AlistairDirector | SSale | −20.6K | $8.49 | −$175.2K | −9.0%208.2K after | |
| Sep 22, 2025 (view filing) | Sep 18 | 4 days | Oki Mark KChief Financial Officer | SSale | −50.1K | $2.92 | −$146.2K | −28.1%127.9K after | |
| Sep 22, 2025 (view filing) | Sep 18 | 4 days | Stewart Richard AlistairChief Executive Officer | SSale | −129.5K | $2.92 | −$378.1K | −36.1%228.9K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Wan JerryPrincipal Accounting Officer | SSale | −14.1K | $2.77 | −$39.0K | −30.1%32.7K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | King Thomas BraxtonDirector | SSale | −139.9K | $2.77 | −$387.4K | −30.7%315.1K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Jacobs CindyPresident & CMO | SSale | −27.6K | $2.77 | −$76.5K | −19.3%115.6K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Xinos JaimeChief Commercial Officer | SSale | −20.9K | $2.77 | −$57.8K | −21.9%74.4K after | |
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Oki Mark KChief Financial Officer | PPurchase | +10.0K | $2.89 | +$28.9K | New position10.0K after | |
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Stewart Richard AlistairChieve Executive Officer | PPurchase | +10.0K | $2.86 | +$28.6K | +19.7%60.9K after | |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Stewart Richard AlistairExecutive Chairman | PPurchase | +10.0K | $4.59 | +$45.9K | +35.1%38.5K after |
Top 10 13F holders, Q3 2026
See all 131 holdersThe largest institutional positions in Achieve Life Sciences, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,614,836 | $61.6M | 1.53% | 00.0% | Unchanged |
| TPG GP A, LLC | 6,877,580 | $55.6M | 1.35% | 00.0% | Unchanged |
| Logos Global Management LP | 5,951,032 | $48.1M | 2.80% | +526,032+9.7% | Added |
| venBio Partners LLC | 5,914,720 | $47.9M | 9.65% | 00.0% | Unchanged |
| VR Adviser, LLC | 5,502,064 | $44.5M | 2.16% | +2,751,032+100.0% | Added |
| BlackRock, Inc. | 5,487,278 | $44.4M | 0.00% | +215,261+4.1% | Added |
| Paradigm Biocapital Advisors LP | 4,951,856 | $40.1M | 0.80% | 00.0% | Unchanged |
| Propel Bio Management, LLC | 3,864,148 | $31.3M | 16.57% | −169,870−4.2% | Reduced |
| Marshall Wace, LLP | 3,770,313 | $30.5M | 0.03% | 00.0% | Unchanged |
| State Street Corp | 3,718,240 | $30.1M | 0.00% | +772,714+26.2% | Added |
Holders of 5% or more of ACHV
See all 11 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Achieve Life Sciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| TPG GP A, LLC | 13D | 12.60%13.8M shares | New | Apr 24, 20261 filing | Apr 24, 2026 | SEC |
| venBio Global Strategic Fund V, L.P. | 13D | 9.99%10.7M shares | New | Apr 27, 20261 filing | Apr 27, 2026 | SEC |
| Logos Global Management LP | 13G/A | 9.99%1.01M shares | – | Nov 16, 20261 filing | Nov 16, 2026 | SEC |
| Paradigm Biocapital Advisors LP | 13G | 9.20%9.90M shares | New | Apr 24, 20261 filing | Apr 24, 2026 | SEC |
| Logos Global Management LP | 13G/A | 8.60%9.70M shares | −1.39 ppfrom 9.99% | Aug 17, 20262 filings | Nov 16, 2026 | SEC |